i Data include people with a diagnosis of HIV infection regardless of stage of disease at diagnosis. ii All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing transmission category, but not for incomplete reporting. iii Heterosexual contact is with a person known to have, or to be at high risk for, HIV infection. iv Other transmission categories include hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
 In 2011, in the United States, among MSM with diagnosed HIV infection: ■ 80.6% were linked to care, ■ 57.5% were retained in care, ■ 52.9% were prescribed antiretroviral therapy (ART), and ■ 44.6% had achieved viral suppression (CDC, 2015a) .
HIV and AIDS Among Transgender People
 Transgender people have been significantly affected by the HIV/AIDS epidemic in the United States.  Transgender women have the highest risk of HIV infection.
■ HIV prevalence in transgender women is an estimated 21.7% (Baral, et al., 2013) . ■ Among male-to-female (MTF) people, 27.7% tested positive for HIV infection, but 11.8% self-reported being HIV positive (CDC, 2015b) . ■ Higher HIV rates (56.3% for test results and 30.8% for self-reporting) were found among MTF Blacks (Herbst, et al., 2008) . ■ By race/ethnicity, Black transgender women have the highest percentage of new HIVpositive test results.
 Transgender people often engage in behaviors that increase the risk of HIV infection, such as:
■ Multiple sex partners or unprotected sex, ■ Commercial sex work, and ■ Use of needle injections for recreational drugs or to alter gender (e.g., hormones, silicone) (Herbst, et al., 2007; Stephens, et al., 2011) .
 Limited data make creating evidence-based HIV prevention interventions that meet the unique needs of transgender populations challenging, so it is imperative to collect data on transgender people.
HIV and AIDS Among People Who Inject Drugs
 Injection drug use leads to approximately 10% of HIV cases in the United States annually (AIDS.gov, 2014).  Injection drug users can get and spread HIV by: ■ Sharing drug preparation or injecting equipment with a person who has HIV. ■ Engaging in risky sexual behaviors with their sex and drug-using partners.
 About 80% of HIV-infected injection drug users in the United States also have hepatitis C (HCV) (AIDS.gov, 2014):
■ HCV leads to cirrhosis of the liver and liver cancer. ■ HCV is more serious in people living with HIV because it leads to liver damage more quickly.
■ Co-infection with HCV also affects treatment of HIV infection, making it important for people who inject drugs to know if they are infected with HCV and to continue to protect themselves. 
HIV and AIDS Policy

HIV and AIDS Measures
New AIDS Cases
vi The treatment guideline for clinical practice in the past was generally to monitor both CD4 T lymphocyte (CD4) cell count and HIV RNA (viral load) concurrently, as markers of the response to ART and HIV disease progression. However, a new recommendation requires the initiation of ART for all HIV-infected individuals regardless of their viral load or CD4 count, weakening the rationale for frequent CD4 monitoring. When a patient is on ART, CD4 count is not useful as it will not guide changes in treatment, according to the U.S. treatment guidelines (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2015) . In addition, reducing the frequency of routine CD4 testing in patients who are virally suppressed can save an estimated $18 million annually, which can be redirected to other HIV care services (Hyle, et al., 2014) . vii Prophylaxis for Mycobacterium avium complex (MAC) is not required among patients receiving ART who are virally suppressed. Studies show that eliminating MAC prophylaxis could reduce pill burden and the risk of drugdrug interactions, along with adverse treatment effects (Yangco, et al., 2014) . With ART, patients can achieve viral suppression and healthy CD4 counts and prevent the onset of secondary infections such as MAC (Buchacz, et al, 2010) . Thus, we do not track specific MAC prophylaxis.
New AIDS cases per 100,000 population age 13 and over, by 
HIV Patients With Viral Load Below 200
Overall Rate:
■ Viral load suppression below 200 copies/mL is desired, as this improves morbidity and mortality for people living with HIV and decreases the chances of spreading HIV. Thus, it is essential for HIV patients to continue to adequately manage the disease, by adhering to antiretroviral therapy and getting regular viral load testing. ■ In 2011, 73.1% of adult HIV patients had a suppressed viral load, defined as HIV RNA less than 200 mL for the first test in the year.  With widespread use of antiretroviral therapy, a better understanding is needed of the patterns and risk factors for cause-specific mortality.
Hepatitis and Deaths of People With HIV Infection
 An estimated one-third of people with HIV are co-infected with hepatitis B or hepatitis C; hepatitis C is more common.  Viral hepatitis progresses faster and causes more liver-related health problems among people with HIV than among those without HIV.  Drug therapy has extended the life expectancy of people with HIV, but hepatitis has become the leading cause of non-AIDS-related death in this population (CDC, 2014) .  Hepatitis C increases the risk of death in HIV patients by about 50% (Branch, et al., 2012) .  Current recommendations are to screen all HIV-infected patients for hepatitis C. ■ Patients at high risk for hepatitis C should be screened annually and whenever this infection is suspected (AIDS Info, 2014).
Antiretroviral Therapy and HIV Deaths
 ART has reduced the death rate of people living with HIV (PLWH), allowing their life expectancy to approach that of the general population.  AIDS-related deaths in PLWH decrease with time on ART, but overall mortality among PLWH remains higher than in the general population.  As the HIV-infected population ages and time on ART increases, causes of death and association with patient characteristics are changing:
■ In high-income countries, deaths from cancer, cardiovascular disease, and liver disease have been identified among PLWH. ■ It is important to study cause-specific mortality to clarify whether these deaths result from effects of ART, prolonged exposure to HIV, restoration of CD4 counts after severe immunosuppression, or aging and non-HIV risk factors.
 Appropriate management based on the complex relationship between associated comorbidities and HIV disease could decrease mortality among PLWH and improve their quality of life (Ingle, et al., 2014) .
Deaths Due to HIV Infection
 Overall Rate: In 2011, the total rate of HIV infection deaths was 2.4 per 100,000 population. HIV infection death rates are decreasing overall and for all racial/ethnic groups and both sexes.
 Groups With Disparities:
■ From 2000 to 2011, HIV infection death rates were higher for Blacks than for Whites.
The disparity between Blacks and Whites is narrowing. ■ In all years, Asians and Pacific Islanders had lower rates than Whites. ■ In all years, the rate of HIV infection deaths was higher for males than for females.
 Achievable Benchmark:
■ The 2008 top 4 State achievable benchmark for HIV deaths was 0.9 per 100,000 population. The top 5 States that contributed to the achievable benchmark are Kansas, Minnesota, Oregon, and Wisconsin. ■ Overall, it would take the total population 6 years to reach the benchmark. At the current rate, Whites, Blacks, and AI/ANs could achieve the benchmark in 3, 8, and 2 years, respectively. APIs have already reached the benchmark. Women would take 3 years and men would take 6 years to achieve the benchmark. 
Ryan White Program Overview
 Since inception, the Ryan White HIV/AIDS Program (RWHAP) has provided funds for primary care and support services for people living with and affected by HIV.  Working with States, cities, and local community organizations, the RWHAP works to improve the quality of HIV-related care for those who lack sufficient health care coverage or financial resources to cope with HIV.  For a second year, we present data from the RWHAP: ■ Data presented are limited to those who received care through the RWHAP. ■ Data are not representative of the entire HIV population, which is estimated to be about 1.2 million people in the United States. 
Ryan White Program Patients Retained in HIV Care
Ryan White program HIV patients who were retained in HIV care (at least 2 ambulatory visit dates at least 90 days apart) by race/ethnicity, income, insurance, and sex ■ In both years, Black and AI/AN HIV-positive clients were less likely to be retained in care than White HIV-positive clients. ■ In both years, HIV-positive clients from low and middle income households were more likely to be retained in care compared with those from high income households. ■ In both years, HIV-positive clients with Medicaid and those without insurance were less likely to be retained in care compared with those with private insurance. ■ In both years, transgender HIV-positive clients were less likely to be retained in care compared with nontransgender male HIV-positive clients. ■ The HIV/AIDS Bureau does not ask the sexual orientation of clients, but it collects variables that portray aspects of sexual orientation, including gender, transgender status, sex at birth, and client risk factors, such as men who have sex with men. For more information, go to https://careacttarget.org/sites/default/files/file-upload/resources/ 2014RSRManual508_0.pdf .
